PCSK9 antibody-based treatment strategies for patients with statin intolerance
E Voutyritsa, C Damaskos, P Farmaki, G Kyriakos… - in vivo, 2021 - iv.iiarjournals.org
Background: Statin intolerance refers to the inability of a patient to tolerate statin therapy,
presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous …
presenting muscle aches, pains, weakness and muscle inflammation. Thus, numerous …
Musculoskeletal adverse events associated with PCSK9 inhibitors: disproportionality analysis of the FDA adverse event reporting system
L Ding, C Chen, Y Yang, J Fang… - Cardiovascular …, 2022 - Wiley Online Library
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have
not been sufficiently explored in clinical trials, including musculoskeletal adverse events …
not been sufficiently explored in clinical trials, including musculoskeletal adverse events …
Evolocumab vs. ezetimibe in statin-intolerant hyperlipidemic Japanese patients: phase 3 GAUSS-4 trial
Aim: In patients with hyperlipidemia, intolerance to statins presents a challenge in reducing
the risk of events associated with cardiovascular disease. This phase 3, randomized, double …
the risk of events associated with cardiovascular disease. This phase 3, randomized, double …
Platycodin D enhances LDLR expression and LDL uptake via down-regulation of IDOL mRNA in hepatic cells
The root of Platycodon grandiflorum (PG) has long been used as a traditional herbal
medicine in Asian country. Platycondin D (PD), triterpenoid saponin that is a main …
medicine in Asian country. Platycondin D (PD), triterpenoid saponin that is a main …
A bifunctional anti-PCSK9 scFv/Exendin-4 fusion protein exhibits enhanced lipid-lowering effects via targeting multiple signaling pathways in HFD-fed mice
M Xu, P Zhang, W Lv, Y Chen, M Chen, Y Leng… - International Journal of …, 2023 - Elsevier
Fusion protein which encompasses more than one functional component, has become one
of the most important representatives of macromolecular drugs for disease treatment since …
of the most important representatives of macromolecular drugs for disease treatment since …
A Retrospective Chart Review Evaluating Efficacy, Tolerability, and Cost of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Older Adults
LE Davis, EK Pogge - High Blood Pressure & Cardiovascular Prevention, 2020 - Springer
Introduction Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are proven to
have profound lowering of low-density lipoprotein cholesterol (LDL-C) in patients with …
have profound lowering of low-density lipoprotein cholesterol (LDL-C) in patients with …
[PDF][PDF] Research Article Musculoskeletal Adverse Events Associated with PCSK9 Inhibitors: Disproportionality Analysis of the FDA Adverse Event Reporting System
L Ding, C Chen, Y Yang, J Fang, L Cao, Y Liu - 2022 - pdfs.semanticscholar.org
Background. Some studies suggest that potential safety issues about PCSK9 inhibitors have
not been sufficiently explored in clinical trials, including musculoskeletal adverse events …
not been sufficiently explored in clinical trials, including musculoskeletal adverse events …